newsfilter
← Latest News
GlobeNewswire·

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 - - Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation - SAN DIEGO and REDWOOD CITY, Cali